Therapeutic Drug Monitoring in the Management of HIV-Infected Patients

Title: Therapeutic Drug Monitoring in the Management of HIV-Infected Patients

Volume: 15 Issue: 19

Author(s): Ivanovic Jelena, Nicastri Emanuele, Ascenzi Paolo, Bellagamba Rita, De Marinis Elisabetta, Notari Stefania, Pucillo Leopoldo Paolo, Tozzi Valerio, Ippolito Giuseppe and Narciso Pasquale

Affiliation:

Keywords: HIV, anti-retroviral therapy, therapeutic drug monitoring, genotypic inhibitory quotient, pharmacogenomics

Abstract: The rate of HIV-positive patients that fails to reach or to maintain a durable virological suppression under anti-retroviral (ARV) therapy might be as high as 50%, therefore new tools to improve ARV drug efficacy are urgently needed. Among others, therapeutic drug monitoring (TDM) is a strategy by which the dosing regimen for a patient is guided by measurement of plasma drug levels, enabling physicians to optimize ARV drug efficacy and to avoid drug-related toxicity. The most used analytical methods to determine plasma levels of ARV drugs are HPLC-UV and HPLC-MS(/MS), recently MALDI-based methods and enzyme immunoassay (EIA) technologies have been also employed. The wide inter-patient variability in ARV drug pharmacokinetic supports the application of TDM to the clinical management of HIV-infected patients. Drug-drug and drug-food interactions, drug binding to plasma proteins, drug sequestering by erythrocytes, hepatic impairment, sex, age, pregnancy, and host genetic factors are sources of inter-patient variability affecting ARV drug pharmacokinetics. Combining the information of TDM and resistance tests in genotypic inhibitory quotient (GIQ) is likely to be of great clinical utility. Indeed, only two clinical trials on GIQ, both conducted using ARV drugs not more commonly in use, have shown clinical benefits. The design of new trials with long follow-up and sample size representative of the current HIV prevalence is urgently needed to give indications for GIQ as an early predictor of virological response. Here, the basic principles and the available methods for TDM in the management of HIV-infected patients are reviewed.

Cite this article as:

Jelena Ivanovic, Emanuele Nicastri, Paolo Ascenzi, Rita Bellagamba, Elisabetta Marinis De, Stefania Notari, Paolo Leopoldo Pucillo, Valerio Tozzi, Giuseppe Ippolito and Pasquale Narciso, Therapeutic Drug Monitoring in the Management of HIV-Infected Patients, Current Medicinal Chemistry 2008; 15 (19) . https://dx.doi.org/10.2174/092986708785132960